Navigation Links
ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
Date:9/6/2011

LOS ANGELES and SINGAPORE, Sept. 6, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the establishment of a wholly owned Singapore-based subsidiary, ImaginAb Molecular Imaging Pte Ltd (IMI). IMI is the first step in the company's international expansion and marks a significant increase in research capability for the organization. IMI will be established to provide GLP pre-clinical molecular imaging services to both the US parent company and select biopharma partnerships, including optical imaging and positron emission tomography (PET) services.

Christian P. Behrenbruch, Ph.D, ImaginAb's CEO, commented, "Singapore has tremendous resources and facilities of interest to ImaginAb. We already have a close dialog with several A*Star Research Institutes (RIs) and a formalized collaboration with Sir David Lane's lab at the Institute of Molecular Biology (IMB)." The establishment of IMI will strengthen the possibility of further collaborations with A*Star, university labs and several global pharmaceutical companies who have established translational medicine units in Singapore.

"Establishing a significant research footprint in Singapore has been a straightforward process, greatly facilitated by the ease of working with A*Star, EDB and other government stakeholders who are committed to bringing highly innovative US companies to a growing and dynamic biotech cluster," commented Dr. Behrenbruch. "We are impressed with the quality of industry-accessible core resources and the international talent base in Singapore. We also expect ImaginAb's footprint in Singapore will also enable the company to better service a rapidly growing client base in Korea, Japan and China."

About ImaginAb, Inc.

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
http://www.profnetconnect.com/anna_wu


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
4. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
5. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
6. Genprex Announces New Branding
7. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
8. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
9. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
10. BD Biosciences Announces Winners of Research Grant Program
11. SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Kong (PRWEB) , ... April 26, 2017 , ... ... hosted in EMEA and North America this May on ... May 16-18 , Donald H. Taylor, Chairman of the Learning and Performance Institute ...
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ... (CL) development tools, and market leader for Semantic Graph Database technology, ... available within the most effective system for developing and deploying applications to solve ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Partners.     , Covalent’s Analytical Services unit provides high-quality data to clients, ... within 24 hours of receipt. There are no price premiums, and customers are ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... manufactures in 10 categories with over 30 nominees and well as the first-year ... the new award and the event was hosted by CompanyWeek and Manufacturers Edge, ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):